How to memorize autonomic pharmacology.

Short answer: you do not memorize autonomic pharmacology, you derive it. Every pathway is the same two-neuron chain, and if you know which transmitter is released at each step and which receptor receives it, every drug effect follows. Learn the map once and the drug lists become predictions instead of facts.

Why the drug lists never stick

Autonomic drug lists fail because they record outputs while hiding the system that produced them. A list tells you that atropine causes dry mouth, blurred vision and urinary retention, which is three facts to store. The receptor map tells you atropine blocks M3, and M3 drives glandular secretion, ciliary contraction and detrusor contraction, which is one fact that generates all three. Every autonomic effect is a receptor doing its normal job in a particular tissue, so the tissue list is downstream of the receptor. That is why students who memorize lists plateau while students who learn the map keep going.

The two-neuron chain

Every autonomic pathway runs through two neurons in series rather than one. A preganglionic neuron leaves the central nervous system and synapses in a ganglion, and a postganglionic neuron then travels from that ganglion to the target tissue [1]. The somatic system, by contrast, runs a single neuron straight to skeletal muscle. That extra synapse is where autonomic pharmacology gets both its complexity and its regularity. Two neurons means two transmitter release points, and each release point has its own receptor to target. Fix that structure first, because everything else hangs off it.

Every ganglion is nicotinic

The ganglion is the step you never have to think about, because it is identical in both divisions. Sympathetic and parasympathetic preganglionic neurons both release acetylcholine, and both act on nicotinic receptors on the postganglionic neuron [2]. Nicotinic receptors are ligand-gated ion channels, so binding opens a pore and depolarises the next neuron directly [2]. Both divisions are cholinergic at the ganglion, and they only diverge afterwards. This single fact removes half the apparent complexity, since it means the difference between sympathetic and parasympathetic lives entirely in the second neuron.

Parasympathetic output is muscarinic

Parasympathetic postganglionic neurons are cholinergic, so they release acetylcholine at the target as well as at the ganglion [2]. The target receptor is muscarinic rather than nicotinic, and muscarinic receptors are G protein-coupled rather than ion channels [2]. That difference in receptor family is why parasympathetic responses are slower and longer-lasting than the millisecond depolarisation at a ganglion. Acetylcholine appears twice in the parasympathetic pathway but acts on a different receptor family each time. A drug can therefore block one without touching the other, which is exactly what antimuscarinic drugs do.

Sympathetic output is adrenergic

Sympathetic postganglionic neurons release noradrenaline instead of acetylcholine, and they act on adrenergic receptors [2]. Those neurons are therefore classified as adrenergic, while parasympathetic postganglionic neurons are classified as cholinergic [2]. Adrenergic receptors are all G protein-coupled and divide into alpha-1, alpha-2, beta-1, beta-2 and beta-3 subtypes. The transmitter switches at the second neuron, and that switch is the entire sympathetic-parasympathetic distinction. Everything else is which subtype sits in which tissue.

The two sympathetic exceptions

Two sympathetic pathways break the noradrenaline rule, and exams reach for both. Sweat glands receive sympathetic innervation but their postganglionic fibres release acetylcholine onto muscarinic receptors, which is why antimuscarinic drugs reduce sweating. The adrenal medulla is stranger still, because preganglionic sympathetic fibres synapse directly on chromaffin cells with no postganglionic neuron at all, releasing acetylcholine onto nicotinic receptors and triggering adrenaline release into the blood. The adrenal medulla behaves like a ganglion whose postganglionic neuron became an endocrine gland. Both exceptions are cholinergic sympathetic pathways, which is the pattern to remember rather than two separate facts.

Muscarinic subtypes worth separating

Three muscarinic subtypes carry almost all the pharmacology you will be asked about. M1 sits in neural tissue and gastric parietal cells, where it drives acid secretion. M2 sits in the heart and slows rate and conduction. M3 sits on glands, smooth muscle and the eye, where it produces secretions, bronchoconstriction, detrusor contraction and miosis. M3 explains the entire antimuscarinic side-effect profile, because blocking it removes secretions, relaxes the detrusor and paralyses accommodation at once. That cluster is worked through in anticholinergic burden in older adults.

How M2 opposes beta-1

The heart is the clearest place to see second messengers decide direction. M2 receptors couple to inhibitory G protein and inhibit adenylate cyclase, which lowers intracellular cyclic AMP [2]. Beta-1 receptors couple to stimulatory G protein and raise cyclic AMP, which increases rate and contractility. The same tissue therefore receives opposing instructions through the same messenger moving in opposite directions [2]. Opposition between the divisions is not two systems fighting, it is one second messenger being pushed up or down from different receptors. This is why blocking one division looks like activating the other.

Alpha subtypes and the presynaptic trick

Alpha-1 is postsynaptic and excitatory on smooth muscle, coupling to Gq to produce vasoconstriction, mydriasis through the iris radial muscle, and bladder sphincter contraction. Alpha-2 is the one that catches students, because it sits presynaptically and couples to Gi. Activating alpha-2 therefore reduces further noradrenaline release, acting as negative feedback, and centrally it reduces sympathetic outflow altogether. An alpha-2 agonist lowers blood pressure, which looks backwards until you notice the receptor is switching the transmitter off rather than on.

Beta subtypes by tissue

Beta-1 is cardiac and renal, raising rate and contractility and triggering renin release from juxtaglomerular cells. Beta-2 is bronchial, vascular and hepatic, producing bronchodilation, vasodilation in skeletal muscle beds and glycogenolysis. Beta-3 acts on adipose tissue and the bladder detrusor. Beta-1 is the pump and beta-2 is the pipes and airways, which is the division that decides whether a beta-blocker is safe in asthma. That consequence is followed through in selective vs nonselective beta-blockers.

The whole map in one table

Receptor maps like this are drilled daily inside the PharmBit app, one mechanism, one trap, five minutes.

Deriving a drug you have never seen

The map earns its keep when an unfamiliar drug appears. Read what the drug does to which receptor, then read that receptor off the table, then apply it to each tissue that carries it. An M3 antagonist reduces secretions, dilates bronchi, relaxes the detrusor and blurs near vision, all from one line of the table. An alpha-1 agonist constricts vessels and dilates the pupil. Four clinical effects come from one receptor lookup, which is the compression the drug lists never give you. Autonomic pharmacology is the clearest case of the general principle set out in how to study pharmacology.

How exams test the map

Questions rarely name the receptor, so they test whether you can work backwards from effects. A patient with dry mouth, blurred vision and urinary retention is an M3 blockade stem. Bradycardia with bronchospasm points at nonselective beta blockade. Sweating that persists when other sympathetic signs are blocked is testing the cholinergic sweat gland exception. The examiner gives you the tissue effects and expects you to name the receptor, which is the map run in reverse. Practising that reversal is more valuable than re-reading the table forwards.

Conclusion

Every autonomic pathway runs preganglionic neuron to ganglion to postganglionic neuron to target. The ganglion is always acetylcholine acting on nicotinic receptors in both divisions, so the divisions differ only at the second neuron. Parasympathetic fibres release acetylcholine onto muscarinic receptors, and sympathetic fibres release noradrenaline onto adrenergic receptors, with sweat glands and the adrenal medulla as the cholinergic exceptions. Receptor subtype and its G protein then decide the direction of the response in each tissue, which is what lets you derive drug effects instead of memorising them.

The vasoactive drugs that act on these receptors are ordered in mcg/kg/min and run in mL/hr: our free infusion rate calculator gives the formula, a worked example and the mistake that costs most marks.

Practice questions

For study only. This post explains pharmacology concepts for exam preparation. It is not medical advice. Always follow your course materials, formulary, and supervisor guidance for clinical decisions.

Keep reading

What does -terol mean?

The -terol stem marks a beta-2 agonist. Why the same receptor causes bronchodilation, tremor and low potassium, and why a long-acting one is never used alone in asthma.

What does -prazole mean?

The -prazole stem marks a proton pump inhibitor. Why irreversible binding makes the effect outlast the drug, why dosing is before food, and the CYP2C19 trap.

What do -azepam and -azolam mean?

The -azepam and -azolam stems mark benzodiazepines. Why frequency rather than duration of channel opening makes them safer than barbiturates, and which are safe in liver disease.

What does -dipine mean?

The -dipine stem marks a dihydropyridine calcium channel blocker acting on vessels rather than the heart. Why that causes ankle oedema and reflex tachycardia.